糖基化蛋白质组学:结构、功能和研究方法

蛋白质糖基化修饰结构多样、分布广泛,以N-糖基化、O-Gal NAc糖基化和O-Glc NAc糖基化等不同修饰形式存在。糖修饰以各种方式广泛参与基本生物学过程,包括基因转录、蛋白质翻译、信号转导、细胞-细胞间以及宿主-病原体相互作用等。糖基化修饰的异常变化与多种重要疾病的发生发展相关,包括免疫性疾病、肿瘤、先天性糖缺陷等。该文系统展示几种常见糖修饰的结构、参与的生理病理过程,以及最新的研究方法,尤其是糖修饰蛋白质或肽段的特异性富集方法和基于质谱的序列分析方法进展,以期丰富糖修饰蛋白质的研究手段,为糖蛋白质功能机制研究、疾病治疗靶标或候选标志物的发现提供新视角。     

表观遗传生物标志物在人类疾病早期诊治中的研究进展

表观遗传修饰异常见于人类的多种疾病(如肿瘤、老年性疾病、发育源性疾病等),影响着这些疾病的发生发展。已有的研究表明,异常表观遗传改变可以作为疾病状态和疾病预测的生物标志物。表观遗传修饰改变的可逆性和可控性也为疾病早期的预防和治疗提供了新策略。本文对DNA甲基化修饰、组蛋白共价修饰、非编码RNA等三种表观遗传方式在肿瘤、老年性疾病和发育源性疾病的研究,以及三者作为表遗传生物标志物在疾病早期诊断和治疗的应用展开介绍,以期为肿瘤、老年性和发育源性相关疾病的诊断与治疗提供借鉴和 参考。     

临床试验进展：生物标志物助推临床开发决策

生物标志物对于疾病的鉴定、早期诊断和预防,以及治疗过程中的监控具有重要作用。寻找和发现有价值的生物标志物已成为目前研究的一个热点。汤森路透Cortellis 临床试验情报将生物标志物的发现与针对当前常见疾病的相关临床试验关联,提供描绘临床图景关键元素和当前趋势的专家分析,从而指导临床开发决策。     

蛋白质O-GlcNAc糖基化的探针

生物大分子包括蛋白质、核酸、糖脂等的动态化学修饰与病理变化的关系,是当今生物医学研究最为重要的前沿领域之一。细胞内蛋白质丝氨酸和苏氨酸侧链羟基的O连N-乙酰葡糖胺(O-GlcNAc)糖基化修饰,参与了基因表达、信号转导、细胞周期等关键生物学过程的精密调控。异常的O-GlcNAc糖基化与肿瘤、糖尿病、神经退行性疾病等慢性疾病的发生发展密切相关。随着质谱检测技术和蛋白质组学的快速发展,目前已经有大量O-GlcNAc糖基化修饰靶蛋白质和位点得到鉴定。而其中多数蛋白质O-GlcNAc糖基化修饰的生理功能亟需通过探针进一步研究。本文对基于抗体、凝集素、代谢途径、化学酶法的O-GlcNAc糖基化探针研究进行归纳总结,发现未来对O-GlcNAc糖基化的研究急需开发针对特定位点的动态化研究探针,其对进一步揭示O-GlcNAc在疾病发生发展过程中的作用至关重要,也是实现临床分子诊断并进行靶向干预的关键。     

晚期糖基化终末产物与糖尿病血管并发症

晚期糖基化终末产物（AGEs）是蛋白质、脂质、核酸等大分子物质的氨基基团与葡萄糖或其他还原糖的醛基在非酶促条件下发生一系列反应生成的稳定的共价加成物。晚期糖基化终末产物（AGEs）通过直接修饰蛋白质、脂质、核酸等或者与其受体相互作用的方式诱导氧化应激反应,引起机体各类细胞发生增生、炎症、纤维化反应、形成血栓等,进而加速人体的衰老或导致多种慢性退化型疾病的发生。本文从糖尿病血管并发症的角度对晚期糖基化终末产物的形成过程、致病机制等予以综述。     

基于蛋白质组学的糖尿病相关生物标记物发现

近年来,随着生活水平的提高和生活方式的转变,我国糖尿病的发病率呈快速上升趋势。然而,目前对糖尿病的发生发展机制仍缺乏系统了解。最近本课题组结合多种蛋白质组学技术对糖尿病的发生发展过程进行研究,发现在大鼠2型糖尿病的发生发展过程中,肝脏线粒体的多个代谢通路蛋白质表达及其修饰发生改变。在人群研究中发现,单氨基酸多态性与肥胖以及糖尿病的发展密切相关。此外,还发现了一些潜在糖尿病相关生物标志物,如载脂蛋白C-I、Ficolin-3等。这些研究有助于完善对糖尿病发病机制的认识,同时也为防治糖尿病提供新的思路与方向。     

临床蛋白质组学———蛋白质组学在临床研究中的应用

临床蛋白质组学是将蛋白质组学技术应用于临床医学研究,它主要围绕疾病的预防、早期诊断和治疗等方面开展研究,其中,恶性肿瘤是临床蛋白质组学研究的一个重点研究对象.由于肿瘤生物标志物对早期诊断具有重要价值,所以临床蛋白质组学的主要目标之一是寻找合适的肿瘤生物标志物,多分子生物标志物已成为寻找肿瘤生物标志物的一个研究趋势.简要介绍了临床蛋白质组学的基本概念,实验设计,临床样本收集与预处理以及蛋白质组学技术在临床研究中的应用与进展.     

吡哆胺-一种天然的AGEs/ALEs抑制剂

衰老及老年相关疾病,如：糖尿病、动脉粥状硬化、各种神经退行性疾病等,与组织蛋白氧化修饰密切相关．在造成蛋白质氧化修饰的反应中,非酶糖基化和脂质过氧化是最重要的两类,它们最终形成非酶糖基化终产物(AGEs)和脂过氧化终产物(ALEs)．基于羰基毒害衰老理论,具有强烈反应活性的羰基类化合物是非酶糖基化和脂质过氧化的共同中间产物,它们是造成蛋白修饰的直接原因之一．吡哆胺是维生素B6的一种天然成分;由于它能直接清除羰基类化合物,从而抑制AGEs／ALEs的生成;又因为吡哆胺对人体副作用很小．因此吡哆胺有望成为一种新型的防治多种老年相关疾病的药物．     

O-GlcNAc修饰对蛋白质泛素化降解途径的影响

O-GlcNAc修饰是一种特殊的糖基化修饰,几乎参与生物体内所有细胞过程的调控。该修饰与泛素化作为两种重要的蛋白质翻译后修饰形式,都与2型糖尿病、神经退行性疾病、癌症等疾病密切相关。O-GlcNAc修饰对蛋白质泛素化降解途径的影响主要体现在4个方面:(1)O-GlcNAc修饰能够抑制26S蛋白酶体的ATPase活性;(2)O-GlcNAc修饰会减少某些底物蛋白的泛素化降解;(3)O-GlcNAc修饰泛素化相关酶并调节其功能;(4)某些蛋白质(包括调控因子)发生O-GlcNAc修饰后间接影响蛋白质泛素化。     

细菌性脑膜炎大鼠模型的尿液蛋白质组学变化

与脑脊液和血液不同,尿液不受到稳态机制的调节,更倾向于积累和反应机体生理和病理状态下的变化。生物标志物的本质特征是变化,因此尿液是寻找疾病早期标志物的更好来源。在世界范围内,细菌性脑膜炎依然是引起新生儿和儿童疾病的主要原因。为了降低死亡率和致残率,需要用无创的方法寻找细菌性脑膜炎的相关线索。本研究中,使用大鼠脑室内注射大肠杆菌模型模拟细菌性脑膜炎,在第1天和第3天的大鼠尿液中寻找尿液蛋白谱的差异变化,为进一步寻找大肠杆菌性脑膜炎的早期生物标记物研究进行初步的探索。通过膜上酶切和胶内酶切将尿蛋白切成肽段并通过液相色谱串联质谱技术(LC-MS/MS)分析肽段信息。第1天的尿液通过胶内酶切方法鉴定到17个差异蛋白,通过膜上酶切鉴定到20个差异蛋白;第3天的尿液通过膜上酶切方法鉴定到5个差异蛋白。这些差异蛋白为寻找细菌性脑膜炎早期生物标志物的初步探索奠定了基础。     

Strategies for the identification of arginine ADP-ribosylation sites

Mono-ADP-ribosylation of arginine is a protein modification in eukaryotic cells regulating protein activity and thereby influencing signal transduction and metabolism. Due to the complexity of the modification and the fragmentation pattern in MS/MS CID experiments, the identification of ADP-ribosylation sites in complex mixtures is difficult. Here we describe a two-step strategy, in the first step enriching and identifying potentially ADP-ribosylated proteins and in the second step identifying the sites of modification by a combination of LC/MS-, LC/MS(E) (MS at elevated fragmentation energy)- and LC/MS/MS experiments. Using this technique we could identify two ADP-ribosylation sites in TNFα digested with trypsin, protease V8 and both proteases and thereby demonstrate the specific ADP-ribosylation of TNFα. In complex samples the detection of ADP-ribosylated peptides requires further enrichment of the modified peptides. We tested various materials routinely used for the isolation of phosphopeptides. IMAC as well as TiO(2) chromatography were successfully applied for the selective enrichment of ADP-ribosylated model peptides.     

A comprehensive peptidome profiling technology for the identification of early detection biomarkers for lung adenocarcinoma

The mass spectrometry-based peptidomics approaches have proven its usefulness in several areas such as the discovery of physiologically active peptides or biomarker candidates derived from various biological fluids including blood and cerebrospinal fluid. However, to identify biomarkers that are reproducible and clinically applicable, development of a novel technology, which enables rapid, sensitive, and quantitative analysis using hundreds of clinical specimens, has been eagerly awaited. Here we report an integrative peptidomic approach for identification of lung cancer-specific serum peptide biomarkers. It is based on the one-step effective enrichment of peptidome fractions (molecular weight of 1,000-5,000) with size exclusion chromatography in combination with the precise label-free quantification analysis of nano-LC/MS/MS data set using Expressionist proteome server platform. We applied this method to 92 serum samples well-managed with our SOP (standard operating procedure) (30 healthy controls and 62 lung adenocarcinoma patients), and quantitatively assessed the detected 3,537 peptide signals. Among them, 118 peptides showed significantly altered serum levels between the control and lung cancer groups (p<0.01 and fold change >5.0). Subsequently we identified peptide sequences by MS/MS analysis and further assessed the reproducibility of Expressionist-based quantification results and their diagnostic powers by MRM-based relative-quantification analysis for 96 independently prepared serum samples and found that APOA4 273-283, FIBA 5-16, and LBN 306-313 should be clinically useful biomarkers for both early detection and tumor staging of lung cancer. Our peptidome profiling technology can provide simple, high-throughput, and reliable quantification of a large number of clinical samples, which is applicable for diverse peptidome-targeting biomarker discoveries using any types of biological specimens.     

A comparison of MS/MS‐based,stable‐isotope‐labeled,quantitation performance on ESI‐quadrupole TOF and MALDI‐TOF/TOF mass spectrometers

The peptide‐based quantitation accuracy and precision of LC‐ESI (QSTAR Elite) and LC‐MALDI (4800 MALDI TOF/TOF) were compared by analyzing identical Escherichia coli tryptic digests containing iTRAQ‐labeled peptides of defined abundances (1:1, 2.5:1, 5:1, and 10:1). Only 51.4% of QSTAR spectra were used for quantitation by ProteinPilot Software versus 66.7% of LC‐MALDI spectra. The average protein sequence coverages for LC‐ESI and LC‐MALDI were 24.0 and 18.2% (14.9 and 8.4 peptides per protein), respectively. The iTRAQ‐based expression ratios determined by ProteinPilot from the 57 467 ESI‐MS/MS and 26 085 MALDI‐MS/MS spectra were analyzed for measurement accuracy and reproducibility. When the relative abundances of peptides within a sample were increased from 1:1 to 10:1, the mean ratios calculated on both instruments differed by only 0.7–6.7% between platforms. In the 10:1 experiment, up to 64.7% of iTRAQ ratios from LC‐ESI MS/MS spectra failed S/N thresholds and were excluded from quantitation, while only 0.1% of the equivalent LC‐MALDI iTRAQ ratios were rejected. Re‐analysis of an archived LC‐MALDI sample set stored for 5 months generated 3715 MS/MS spectra for quantitation, compared with 3845 acquired originally, and the average ratios differed by only 3.1%. Overall, MS/MS‐based peptide quantitation performance of offline LC‐MALDI was comparable with on‐line LC‐ESI, which required threefold less time. However, offline LC‐MALDI allows the re‐analysis of archived HPLC‐separated samples.     

Identification of the major site of O-linked beta-N-acetylglucosamine modification in the C terminus of insulin receptor substrate-1

Signal transduction from the insulin receptor to downstream effectors is attenuated by phosphorylation at a number of Ser/Thr residues of insulin receptor substrate-1 (IRS-1) resulting in resistance to insulin action, the hallmark of type II diabetes. Ser/Thr residues can also be reversibly glycosylated by O-linked beta-N-acetylglucosamine (O-GlcNAc) monosaccharide, a dynamic posttranslational modification that offers an alternative means of protein regulation to phosphorylation. To identify sites of O-GlcNAc modification in IRS-1, recombinant rat IRS-1 isolated from HEK293 cells was analyzed by two complementary mass spectrometric methods. Using data-dependent neutral loss MS3 mass spectrometry, MS/MS data were scanned for peptides that exhibited a neutral loss corresponding to the mass of N-acetylglucosamine upon dissociation in an ion trap. This methodology provided sequence coverage of 84% of the protein, permitted identification of a novel site of phosphorylation at Thr-1045, and facilitated the detection of an O-GlcNAc-modified peptide of IRS-1 at residues 1027-1073. The level of O-GlcNAc modification of this peptide increased when cells were grown under conditions of high glucose with or without chronic insulin stimulation or in the presence of an inhibitor of the O-GlcNAcase enzyme. To map the exact site of O-GlcNAc modification, IRS-1 peptides were chemically derivatized with dithiothreitol following beta-elimination and Michael addition prior to LC-MS/MS. This approach revealed Ser-1036 as the site of O-GlcNAc modification. Site-directed mutagenesis and Western blotting with an anti-O-GlcNAc antibody suggested that Ser-1036 is the major site of O-GlcNAc modification of IRS-1. Identification of this site will facilitate exploring the biological significance of the O-GlcNAc modification.     

Application of proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody standardization program sample subset

Novel biomarkers of type 1 diabetes must be identified and validated in initial, exploratory studies before they can be assessed in proficiency evaluations. Currently, untargeted "-omics" approaches are underutilized in profiling studies of clinical samples. This report describes the evaluation of capillary liquid chromatography (LC) coupled with mass spectrometry (MS) in a pilot proteomic analysis of human plasma and serum from a subset of control and type 1 diabetic individuals enrolled in the Diabetes Autoantibody Standardization Program, with the goal of identifying candidate biomarkers of type 1 diabetes. Initial high-resolution capillary LC-MS/MS experiments were performed to augment an existing plasma peptide database, while subsequent LC-FTICR studies identified quantitative differences in the abundance of plasma proteins. Analysis of LC-FTICR proteomic data identified five candidate protein biomarkers of type 1 diabetes. alpha-2-Glycoprotein 1 (zinc), corticosteroid-binding globulin, and lumican were 2-fold up-regulated in type 1 diabetic samples relative to control samples, whereas clusterin and serotransferrin were 2-fold up-regulated in control samples relative to type 1 diabetic samples. Observed perturbations in the levels of all five proteins are consistent with the metabolic aberrations found in type 1 diabetes. While the discovery of these candidate protein biomarkers of type 1 diabetes is encouraging, follow up studies are required for validation in a larger population of individuals and for determination of laboratory-defined sensitivity and specificity values using blinded samples.     

The association of a distinct plasma proteomic profile with the cervical high-grade squamous intraepithelial lesion of Uyghur women: a 2D liquid-phase chromatography/mass spectrometry study

Objective: To identify plasma protein biomarkers of cervical high-grade squamous intraepithelial lesion (HSIL) of Uyghur women by proteomics approach.

Methods: Plasma protein samples of Uyghur women with HSIL and chronic cervicitis were analyzed with 2D HPLC followed by detection of target proteins with Linear Trap Quadrupole Mass Spectrometer (LTQ MS/MS).

Results: We detected three upregulated and one downregulated protein peaks representing protein constituents distinguishing HSIL from controls by 2D HPLC, identified 31 target proteins by LTQ MS/MS. Further confirmed analysis with online software IPA^® 8.7 and ELISA assay showed APOA1 and mTOR as potential biomarkers.

Conclusions: A distinct plasma proteomic profile may be associated with HSIL of Uyghur women.     

Identification of novel serum peptides biomarkers for female breast cancer patients in Western China

This study aimed to identify novel serum peptides biomarkers for female breast cancer (BC) patients. We analyzed the serum proteomic profiling of 247 serum samples from 96 BC patients, 48 additional paired pre‐ and postoperative BC patients, 39 fibroadenoma patients as benign disease controls, and 64 healthy controls, using magnetic‐bead‐based separation followed by MALDI‐TOF MS. ClinProTools software identified 78 m/z peaks that differed among all analyzed groups, ten peaks were significantly different (P < 0.0001), with Peaks 1–6 upregulated and Peaks 7–10 downregulated in BC. Moreover, three peaks of ten (Peak 1, m/z: 2660.11; Peak 2, m/z: 1061.09; Peak 10, m/z: 1041.25) showed a tendency to return to healthy control values after surgery. And these three peptide biomarkers were identified as FGA605‐629, ITIH4 347–356, and APOA2 43–52. Methods used in this study could generate serum peptidome profiles of BC, and provide a new approach to identify potential biomarkers for diagnosis as well as prognosis of this malignancy.     

Proteome analysis of serum from type 2 diabetics with nephropathy

Diabetic nephropathy (DN) is a renal disease which develops as a consequence of diabetes mellitus. Microalbuminuria is the earliest clinical sign of DN. There are no specific diagnostic biomarkers for type 2 diabetics with nephropathy other than microalbuminuria and macroalbuminuria. However, microalbuminuria does not constitute a sole independent indicator for type 2 diabetics with nephropathy, and thus, another screening method, such as a biomarker assay, is required in order to diagnose it more correctly. Therefore, we have utilized two-dimensional electrophoresis (2-DE) to identify human serum protein markers for the more specific and accurate prediction of progressive nephropathy in type 2 diabetes patients, via comparisons of the serum proteome in three experimental groups: type 2 diabetes patients without microalbuminuria (DM, n = 30), with microalbuminuria (MA, n = 29), and with chronic renal failure (CRF, n = 31). As a result, proteins which were differentially expressed with statistical significance (p < 0.05) in MA and CRF groups as compared to those in DM group were selected and identified by ESI-Q-TOF MS/MS. Among these identified proteins, two proteins which might be useful as diagnostic biomarkers of type 2 diabetics with nephropathy were verified by Western blotting: extracellular glutathione peroxidase (eGPx) and apolipoprotein (ApoE) were found to exhibit a progressive reduction in MA and CRF groups. Notably, eGPx was further verified by ELISA using DM (n = 100) and MA (n = 96) patient samples. Collectively, our results show that the two proteins identified in this study may constitute potential biomarkers for the diagnosis of type 2 diabetics with nephropathy.     

Quantitative Detection of 15 Serum Bile Acid Metabolic Products by LC/MS/MS in the Diagnosis of Primary Biliary Cholangitis

To determine 15 bile acid metabolic products in human serum by liquid chromatography-tandem mass spectrometry (LC/MS/MS) and value their diagnostic outcome in primary biliary cholangitis (PBC). Serum from 20 healthy controls and 26 patients with PBC were collected and went LC/MS/MS analysis of 15 bile acid metabolic products. The test results were analyzed by bile acid metabolomics, and the potential biomarkers were screened and their diagnostic performance was judged by statistical methods such as principal component and partial least squares discriminant analysis and area under curve (AUC). 8 differential metabolites can be screened out: Deoxycholic acid (DCA), Glycine deoxycholic acid (GDCA), Lithocholic acid (LCA), Glycine ursodeoxycholic acid (GUDCA), Taurolithocholic acid (TLCA), Tauroursodeoxycholic acid (TUDCA), Taurodeoxycholic acid (TDCA), Glycine chenodeoxycholic acid (GCDCA). The performance of the biomarkers was evaluated by the AUC, specificity and sensitivity. In conclusion, DCA, GDCA, LCA, GUDCA, TLCA, TUDCA, TDCA and GCDCA were identified as eight potential biomarkers to distinguish between healthy people and PBC patients by multivariate statistical analysis, which provided reliable experimental basis for clinical practice.